Communiqués de presse

décembre

• 15/12/2017 - Bone Therapeutics Provides Update on Equity Placement
• 14/12/2017 - Bone Therapeutics Launches Equity Placement
• 11/12/2017 - Bone Therapeutics and Cellthera Pharm LLC announce intention to collaborate and Bone Therapeutics provides overview of its pipeline

novembre

• 09/11/2017 - Bone Therapeutics Business Update for Third Quarter 2017

octobre

• 24/10/2017 - Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017
• 13/10/2017 - The preliminary documents for the Extraordinary General Shareholder Meeting on 30 October 2017 have been made available

septembre

• 22/09/2017 - Bone Therapeutics and Asahi Kasei sign exclusive license agreement for PREOB in Japan
• 20/09/2017 - Bone Therapeutics announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis
• 14/09/2017 - Bone Therapeutics reports strong interim results from ALLOB Phase IIA spinal fusion study
• 04/09/2017 - The preliminary documents for the Extraordinary General Shareholder Meeting on 5 October 2017 have been made available

août

• 31/08/2017 - Bone Therapeutics announces H1 results for 2017
• 31/08/2017 - Bone Therapeutics appoints Jean-Luc Vandebroek as Chief Financial Officer
• 24/08/2017 - Bone Therapeutics Notice of Half Year 2017 Results

juillet

• 03/07/2017 - Bone Therapeutics strengthens board of directors

juin

• 26/06/2017 - Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell  therapy platform
• 08/06/2017 - Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB

mai

• 29/05/2017 - Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors
• 11/05/2017 - Bone Therapeutics Business Update for First Quarter 2017

avril

• 26/04/2017 - Bone Therapeutics: The preliminary documents for the Annual General Shareholder Meeting on 26 May 2017 have been made available
• 25/04/2017 - Bone Therapeutics announces the publication of its Annual Report 2016

mars

• 16/03/2017 - Bone Therapeutics Reports Full Year 2016 Results
• 10/03/2017 - Bone Therapeutics to participate in upcoming key investor conferences
• 09/03/2017 - Bone Therapeutics completes recruitment of 16 patients in ALLOB Phase I/IIA delayed-union study
• 06/03/2017 - Bone Therapeutics Strengthens Clinical Development Leadership with Appointment of Dr. Miguel Forte as Chief Medical Officer
• 03/03/2017 - Bone Therapeutics Notice of Full Year 2016 Results

janvier

• 20/01/2017 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2017
• 17/01/2017 - Bone Therapeutics Provides Business Update for Q4 2016
• 06/01/2017 - Bone Therapeutics Granted EUR 2.3 Million in Non-Dilutive Funding by the Walloon Region

décembre

• 21/12/2016 - Bone Therapeutics announces its financial calendar for 2017

novembre

• 08/11/2016 - Bone Therapeutics Business Update for Third Quarter 2016
• 02/11/2016 - Bone Therapeutics Notice of Q3 2016 Results - Results to be announced on 8 November 2016

octobre

• 11/10/2016 - Enrico Bastianelli to stand down as CEO of Bone Therapeutics
• 11/10/2016 - Transparency notification received from Theodorus II SA
• 05/10/2016 - Bone Therapeutics reports positive efficacy data for the ALLOB® Phase IIA spinal fusion trial

septembre

• 15/09/2016 - Bone Therapeutics receives positive ruling on Belgian Patent Income Deduction

août

• 30/08/2016 - Bone Therapeutics announces H1 results for 2016
• 25/08/2016 - Bone Therapeutics Half Year 2016 Results to be announced on 30 August 2016

juin

• 08/06/2016 - Bone Therapeutics demonstrates superiority of PREOB® in Phase IIB osteonecrosis study presented at EULAR
• 03/06/2016 - Bone Therapeutics celebrates ten years of innovation in bone cell therapy

mai

• 19/05/2016 - Bone Therapeutics to enhance value of its severe osteoporosis program by transitioning to allogeneic development
• 17/05/2016 - Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial
• 10/05/2016 - Bone Therapeutics Provides Business Update for the First Quarter of 2016
• 03/05/2016 - Bone Therapeutics completes recruitment of its ALLOB®Phase IIA spinal fusion study

avril

• 26/04/2016 - The preliminary documents for the Annual General Shareholder Meeting on 26 May 2016 have been made available
• 14/04/2016 - Bone Therapeutics announces the publication of its Annual Report 2015

mars

• 29/03/2016 - Bone Therapeutics Reports Full Year 2015 Results
• 29/03/2016 - Bone Therapeutics reports initial efficacy results from its PREOB® Phase IIA trial in severe osteoporosis
• 16/03/2016 - Bone Therapeutics Notice of Full Year 2015 Results: Results to be announced on 29 March 2016

février

• 24/02/2016 - Bone Therapeutics presents ALLOB® pre-clinical and early clinical efficacy data in spinal fusion at the Clinical Applications of Stem Cells Conference
• 17/02/2016 - Bone Therapeutics Provides Business Update for the Fourth Quarter of 2015
• 17/02/2016 - Bone Therapeutics treats 12 patients without safety concerns in ALLOB® Phase IIA spinal fusion trial
• 02/02/2016 - Bone Therapeutics extends Kasios collaboration

janvier

• 20/01/2016 - Bone Therapeutics réaffirme son éligibilité au PEA-PME pour 2016
• 18/01/2016 - Bone Therapeutics expands its delayed-union program with ALLOB® into multiple fractures
• 13/01/2016 - Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2016
• 05/01/2016 - Bone Therapeutics Granted an Additional EUR 2 Million in Non-Dilutive Funding by the Walloon Region

décembre

• 23/12/2015 - Bone Therapeutics announces its financial calendar for 2016
• 15/12/2015 - Bone Therapeutics completes recruitment of the first half of patients in ALLOB® Phase IIA spinal fusion trial
• 11/12/2015 - ALLOB® Delayed-Union Program Awarded at Cells Orthopedics Conference

novembre

• 30/11/2015 - Bone Therapeutics Awarded EUR 3 million in Funding to Support New Research Projects
• 18/11/2015 - Bone Therapeutics Provides Business Update for the Third Quarter of 2015
• 12/11/2015 - Bone Therapeutics’ ALLOB® receives Orphan Drug Designation for Osteogenesis Imperfecta from the EMA and FDA
• 09/11/2015 - Bone Therapeutics Appoints Thomas Lienard as Chief Business Officer

octobre

• 22/10/2015 - Transparency notification received from S.R.I.W. SA & Sofipôle SA
• 13/10/2015 - Bone Therapeutics to participate in key investor conferences in Q4 2015

septembre

• 28/09/2015 - Bone Therapeutics treats first patients in pioneering trial for minimally invasive treatment of failed spinal fusion
• 22/09/2015 - Bone Therapeutics announces half-year results for 2015
• 21/09/2015 - Bone Therapeutics Notice of Half Year Results 2015
• 07/09/2015 - Bone Therapeutics treats second patient cohort in ALLOB® Phase I/IIA delayed-union fracture trial

juin

• 22/06/2015 - Bone Therapeutics reports first results of its Phase IIA trial for PREOB® in severe osteoporosis

mai

• 15/05/2015 - Bone Therapeutics Provides Business Update for the First Quarter 2015

avril

• 28/04/2015 - Bone Therapeutics Reports 2014 Financial and Operational Results
• 24/04/2015 - Bone Therapeutics officially opens its new headquarters in Gosselies
• 13/04/2015 - Bone Therapeutics Establishes US Subsidiary

mars

• 23/03/2015 - Bone Therapeutics treats first patients in ALLOB® Phase IIA spinal fusion trial
• 02/03/2015 - Bone Therapeutics accelerates its ALLOB® Phase I/IIA Delayed-Union trial

février

• 19/02/2015 - Information on the total number of voting rights and shares
• 18/02/2015 - Bone Therapeutics announces its financial calendar for 2015
• 17/02/2015 - Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA
• 16/02/2015 - Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015
• 11/02/2015 - Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million
• 04/02/2015 - Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris

janvier

• 21/01/2015 - Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris
• 19/01/2015 - Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial
• 16/01/2015 - Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris
• 05/01/2015 - Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product

décembre

• 04/12/2014 - Bone Therapeutics Authorised to Enrol patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB®

novembre

• ALLOBIF Collaboration
• 17/11/2014 - Bone Therapeutics and Kasios to collaborate on novel product for the optimisation of spinal fusion procedures

octobre

• Bone Therapeutics extends ALLOB® phase I/IIa trial to Germany

septembre

• Bone Therapeutics receives clearance for ALLOB® phase II trial in spine fusion
• Bone Therapeutics supports pioneering research by backing projects vital to regenerative medicine research (EN)

juillet

• Bone Therapeutics and Partners awarded over €0.5 million M-ERA.net research funding to develop 3-D patient-tailored bone tissue engineered products

juin

• Bone Therapeutics Starts Patient Treatment in First Ever Clinical Trial with Allogeneic Bone Cell Therapy Product

janvier

• Bone Therapeutics to present at Biotech Showcase in San Francisco on Tuesday 14 January, 2014 at 10.15am

décembre

• Bone Therapeutics and partners awarded highly competitive €3.8 million Marie Curie research grant

novembre

• Bone Therapeutics’ pivotal phase III osteonecrosis trial with PREOB® hits a new milestone - 30 centres across Europe now active
• Bone Therapeutics treats first patients in PREOB® pivotal phase IIb/III trial for the treatment of non-union fractures

octobre

• Bone Therapeutics receives clearance for ALLOB® phase I/IIa trial

septembre

• Bone Therapeutics Appoints Wim Goemaere as Chief Financial Officer

juin

• Establishment of the Walloon Cell Therapy Platform: The platform aims to produce cell therapy medicines on a large scale
• Fondation de la Plateforme Wallonne de Thérapie Cellulaire: La plateforme vise à produire les médicaments de thérapie cellulaire à grande échelle

avril

• Bone Therapeutics and Erasme University Start Phase IIa Trial in Osteoporosis with its Cell Therapy Product PREOB®
• Bone Therapeutics to Present at Upcoming Investor Conferences

mars

• Bone Therapeutics Awarded Manufacturing Authorisation and European Approval to Produce Allogeneic Bone Cell Therapy Products

février

• Bone Therapeutics Invests in Cell Therapy Manufacturing Facility

janvier

• Bone Therapeutics Raises €7.7 Million in Series D Fundraising

octobre

• Bone Therapeutics receives clearance for its pivotal phase III osteonecrosis trial with PREOB® in Europe and treats the first patients in the study
• Bone Therapeutics reçoit l'approbation des autorités et traite les premiers patients dans son étude clinique de phase III en ostéonécrose avec son produit PREOB®

février

• Bone Therapeutics lève 9,5M €

juin

• Bone Therapeutics entre dans une nouvelle Phase de son développement Industriel